NCT03623373已完成2 期
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Stem Cell Mobilization Success Rate With Cytarabine and Rituximab
研究概览
简要总结
This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a preparation for a larger cooperative group trial with the goal of achieving a standard induction regimen for MCL in transplant eligible patients. The investigators hypothesize that the addition of acalabrutinib to BR/CR regimen will prove safe and increase the complete response (CR) rate as well as minimal residual disease (MRD) negativity pre-transplant, thus improving clinical outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed mantle cell lymphoma with documented expression of Cyclin D1 by immune-histochemical stains and/or t(11;14) by cytogenetics or FISH.
- •Presence of evaluable disease by PET imaging per the Lugano classification.
- •Eligible for autologous stem cell transplantation.
- •Between 18 and 70 years of age, inclusive.
- •ECOG performance status ≤ 2
- •Normal bone marrow and organ function as defined below:
- •Absolute neutrophil count ≥ 1,000/mcL unless, in the opinion of the treating physician, neutropenia is due to splenomegaly or bone marrow involvement
- •Platelets ≥ 100,000/mcL unless, in the opinion of the treating physician, thrombocytopenia is due to splenomegaly or bone marrow involvement
- •Total bilirubin ≤ 2.0 x IULN and AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN except when, in the opinion of the treating physician, elevation is due to direct involvement of lymphoma (e.g. hepatic infiltration or biliary obstruction due to lymphoma) or Gilbert's disease
- •Creatinine ≤ IULN OR creatinine clearance ≥ 40 mL/min for patients with creatinine levels above institutional normal
- •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
排除标准
- •Any previous chemotherapy or radiation for mantle cell lymphoma. Short course of steroids for symptom relief prior to presentation is permissible.
- •Symptomatic meningeal or parenchymal brain lymphoma.
- •Prior exposure to a BTK inhibitor.
- •Currently receiving any other investigational agents.
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to acalabrutinib, rituximab, cytarabine, bendamustine, or other agents used in the study.
- •Received a live virus vaccination within 28 days of first dose of study drug.
- •Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec at screening. Exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
- •Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
- •Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease).
- •Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura).
- •Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
- •Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.
- •Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
- •Prothrombin time (PT)/INR or aPTT (in the absence of lupus anticoagulant) >2x ULN. Exception: Subjects receiving warfarin are excluded; however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the PI.
- •Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
- •History of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug.
- •Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
- •Subjects with serologic status reflecting active viral hepatitis B or C infection. Subjects who are hepatitis B core antibody positive but surface antigen negative will need negative polymerase chain reaction (PCR) prior to enrollment. Hepatitis B surface antigen positive or PCR positive patients will be excluded. Subjects who are hepatitis C antibody positive will need negative PCR prior to enrollment. Subjects with positive hepatitis C PCR will be excluded.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry.
- •Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with acalabrutinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
研究组 & 干预措施
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Leukapheresis (Procedure)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Peripheral blood (Procedure)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Oral rinse (Procedure)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Bone marrow collection (Procedure)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Bendamustine (Drug)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Rituximab (Drug)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Acalabrutinib (Drug)
Bendamustine/Rituximab/Acalabrutinib/Cytarabine
Experimental
- Patients will receive (6) 28 day cycles
- Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
- Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
- After Cycle 6, patients will undergo leukapheresis
干预措施: Cytarabine (Drug)
结局指标
主要结局
Stem Cell Mobilization Success Rate With Cytarabine and Rituximab
时间窗: Through 5 courses of apheresis (up to 5 days)
-Stem cell mobilization success is defined as a yield of \>2x10\^6 CD34+ stem cells/kg with a maximum of 5 courses of apheresis
次要结局
- Pre-transplant Complete Response Rate(Through completion of treatment (estimated to be 6 months))
- Progression-free Survival (PFS)(Through 5 years)
- Safety and Tolerability of Regimen in Subjects With MCL as Measured by Treatment Related Non-hematologic Toxicity of Grade 3 or Higher(30 days following completion of treatment (estimated to be 7 months))
- Overall Response Rate (ORR = Complete Response (CR) + Partial Response (PR)) of Subjects(Through completion of treatment (estimated to be 6 months))
- Overall Survival (OS)(Through 5 years)
- Median Progression-free Survival (PFS)(Up to approximately 5 years of follow-up)
- Overall Survival (OS)(Up to approximately 5 years of follow-up)
- Median Overall Survival (OS)(Up to approximately 5 years of follow-up)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLMantle Cell Lymphoma (MCL)NCT02717624Acerta Pharma BV72
进行中（未招募）
3 期
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLLymphoma, Mantle CellNCT02972840Acerta Pharma BV635
进行中（未招募）
2 期
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasRefractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHLDiffuse Large B-cell Lymphoma (DLBCL)De Novo or Transformed Indolent B-cell LymphomaDLBCL, Nos Genetic SubtypesT Cell/Histiocyte-rich Large B-cell LymphomaEBV-Positive DLBCL, NosPrimary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)High-Grade B-Cell Lymphoma, NosC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaGrade 3b Follicular LymphomaC-MYC/BCL2 Double-Hit High-Grade B-Cell LymphomaNCT05583149Patrick C. Johnson, MD28
进行中（未招募）
3 期
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLChronic Lymphocytic LeukemiaNCT03836261Acerta Pharma BV984
招募中
2 期
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLDiffuse Large B-Cell LymphomaNCT05952024AstraZeneca80